Why the study?
How should bleeding be managed in patients receiving novel oral anticoagulants in the perioperative setting?
How should bleeding be managed in patients receiving novel oral anticoagulants in the perioperative setting?
This review highlights that while hemodialysis may help reverse dabigatran and prothrombin complex concentrates may reverse rivaroxaban, further clinical studies are needed to establish optimal bleeding management for novel oral anticoagulants.
Answers are grounded in this paper and cite their sources.
May guide perioperative NOAC bleeding management with hemodialysis for dabigatran and PCC for rivaroxaban; leaves open confirmation in prospective trials.
Managing patients in the perioperative setting receiving novel oral anticoagulation agents for thromboprophylaxis or stroke prevention with atrial fibrillation is an important consideration for clinicians. The novel oral anticoagulation agents include direct Factor Xa inhibitors rivaroxaban and apixaban, and the direct thrombin inhibitor dabigatran. In elective surgery, discontinuing their use is important, but renal function must also be considered because elimination is highly dependent on renal elimination. If bleeding occurs in patients who have received these agents, common principles of bleeding management as with any anticoagulant (including the known principles for warfarin) should be considered. This review summarizes the available data regarding the management of bleeding with novel oral anticoagulation agents. Hemodialysis is a therapeutic option for dabigatran-related bleeding, while in vitro studies showed that prothrombin complex concentrates are reported to be useful for rivaroxaban-related bleeding. Additional clinical studies are needed to determine the best method for reversal of the novel oral anticoagulation agents when bleeding occurs.
No takes yet. Share an insight, caveat, or question.
Levy et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: